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Abstract Anthracycline chemotherapy maintains a promi-
nent role in treating many forms of cancer. Cardiotoxic side
effects limit their dosing and improved cancer outcomes ex-
pose the cancer survivor to increased cardiovascular morbidity
and mortality. The basic mechanisms of cardiotoxicity may
involve direct pathways for reactive oxygen species genera-
tion and topoisomerase 2 as well as other indirect pathways.
Cardioprotective treatments are few and those that have been
examined include renin angiotensin system blockade, beta
blockers, or the iron chelator dexrazoxane. New treatments
exploiting the ErbB or other novel pro-survival pathways,
such as conditioning, are on the cardioprotection horizon.
Even in the forthcoming era of targeted cancer therapies, the
substantial proportion of today’s anthracycline-treated cancer
patients may become tomorrow’s cardiac patient.
Keywords Cancer anthracycline doxorubicin chemotherapy
cardiotoxicity cardioprotection
Introduction
Cancer outcomes continue to improve due to earlier detection
and newer targeted therapies, with anthracycline chemotherapy
playing a major role in the modern era of cancer treatment. The
serendipitous discovery of doxorubicin from Streptomyces
peucetius and its precursor daunorubicin was a milestone in
antibiotic overproduction techniques of the day [1].
Anthracyclines are listed among the World Health
Organisation (WHO) model list of essential medicines [2].
Fifty years on from its discovery, anthracycline anti-tumour
and cardiotoxic mechanisms alike continue to evoke consider-
able interest in basic science and clinical trials research.
Cancer now affects more than one in three people in their
lifetime, and along with cardiovascular disease, they are the
two leading causes of death in developed nations. Overall ten-
year cancer survival stands at 50% across the twenty most
common malignancies and approximately 80% or better in
breast, lymphoma, melanoma and uterine cancers. These mor-
tality trends reflect a broad improvement in survival rates in
the developed economies [3]. In the United Kingdom survival
trends have doubled in adults in the last 40 years and tripled in
children since the 1960s [4]. Paradoxically, improved long
term cancer survival has led to an increased awareness of the
adverse cardiac effects of cancer treatment itself. These wel-
come improvements have thus shifted the care paradigm from
cancer survival to cancer survivorship.
The Role of Anthracyclines – today’s Cancer Patients
Are tomorrow’s Cardiac Patients
New biological and small molecule treatments have dramatical-
ly improved the outlook of many cancers over the last 15 years
[5–7]. Even in this encouraging context, anthracycline chemo-
therapy regimens play a prominent role in many cancer treat-
ments – e.g.32% of breast cancer patients [8], 57 to 70% of
elderly lymphoma patients [9, 10], and 50 to 60% of childhood
cancer survivors are treated with an anthracycline regimen [11].
Thus, with long term cancer survivorship there will be a sub-
stantial population of cancer patients who will continue to re-
main at risk of early cardiovascular morbidity andmortality due
to their legacy anthracycline chemotherapy [12, 13].
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Anthracyclines: Structure, Targets and Toxicity
The four most common anthracyclines are doxorubicin, dau-
norubicin, epirubicin and idarubicin (Fig. 1). Doxorubicin and
daunorubicin were the first to be used in clinical practice.
Epirubicin, a stereoisomer of doxorubicin, has an increased
volume of distribution and longer half-life than doxorubicin
(doxorubicin t½ = 1–3 h, epirubicin 31–35 h). Idarubicin, a
derivative of daunorubicin, is more lipophilic and has a higher
cellular uptake than daunorubicin.
Mechanisms of Action
The exact mechanism of anthracycline-induced cardiotoxicity
remains unclear, though it is likely to be multifactorial. Until
recently, the most widely accepted hypothesis was that
anthracyclines interfered with redox cycling, resulting in
DNA damage due to reactive oxygen species (ROS) produc-
tion [14]. More recently, topoisomerase 2 has been suggested
to be the main mediator of cardiotoxicity, though other mech-
anisms contribute. (Fig. 2)
The Role of Reactive Oxidation Species
The quinone moiety of anthracyclines are susceptible to uni-
valent reduction to a semiquinone radical by a number of
cellular oxido-reductases. In myocardial cells, this is
predominantly achieved via an enzymatic pathway involving
NADH dehydrogenase (complex I) of the mitochondrial elec-
tron transport chain [15]. In the presence of molecular oxygen,
the semiquinone auto-oxidises to generate the parent
anthracycline and a superoxide anion [16]. This non-
enzymatic pathway allows a self-perpetuating redox cycle to
be established, resulting in the accumulation of superoxide
anions. ROS levels may also be increased by free cellular iron
and potentiating ferrous-ferric cycling of molecular iron [17].
The doxorubicin-iron complexes form toxic radical and reac-
tive nitrogen species, resulting in increased nitrosative stress
and mitochondrial dysfunction [18].
The Role of Topoisomerase 2β
DNA topoisomerases (Top) induce temporary single or
double-stranded breaks to regulate the topological changes
during DNA replication, transcription, recombination and
chromatin remodelling [19]. In humans, Top2 is expressed
as isoenzymes Top2α and Top2β [20]. Top2α is the most
prevalent and is highly expressed in proliferating (malignant
and non-malignant) cells. It is essential for chromosomal seg-
regation and its expression varies during the cell cycle,
peaking during G2/M phases [21]. Conversely, Top2β is more
abundant in quiescent cells, such as adult mammalian
cardiomyocytes, and its expression remains constant through-
out the cell cycle.
Fig. 1 The four anthracycline derivatives Doxorubicn (DOX),
Daunarubicin (DNR), Epirubicin (EPI) and Idarubicin (IDA). The
anthracyclines share a tetracyclic aglycone structure of four cyclohexane
chains with a daunosamine sugar moiety at carbon C7 of ring a; adjacent
quinone-hydroquinone groups in rings b and c; a methoxy substituent
carbon C4 in ring D; a carbonyl group at C13; and a short side chain in
C9. Doxorubicin and daunorubicin differ in their short chains.
Doxorubicin has a primary alcohol, whereas daunorubicin has a methyl
group. Epirubicin is derived from doxorubicin by axial-to-equitorial
epimerisation of the hydroxyl group in the daunosamine moiety.
Idarubicin is identical to daunorubicin except the 4-methoxy group in
ring D is removed
64 Cardiovasc Drugs Ther (2017) 31:63–75
Doxorubicin exerts its cytotoxic effect by intercalating
DNA. Doxorubicin binds with DNA and topoisomerase 2
isoenzmes forming a ternary Top2-doxorubicin-DNA com-
plex, which causes double-stranded DNA breaks. When
bound to Top2α, the complex inhibits DNA replication; ar-
rests the cell cycle in G1/G2; and induces apoptosis [22] as
intended in proliferating malignant cells. Conversely, when
bound to Top2β, mitochondrial dysfunction is triggered by
the suppression of peroxisome proliferator-activated receptor
(PPAR), which regulates oxidative metabolism [23], In adult
mammalian cardiomyocytes, this leads to an activation of al-
tered P53 tumour suppressor pathway, β-adrenergic signal-
ling, impaired calcium handling, mitochondrial dysfunction
and increased apoptosis. Without Top2β, doxorubicin cannot
bind directly to DNA [22]. Animal studies with Top2β knock-
out (KO) mice have shown that the absence of Top2β protects
against doxorubicin-induced cardiotoxicity [24, 25] partially
due to reduced mitochondrial dysfunction [25].
ErbB2/ErbB4 and NRG-1 Signalling
Anthracyclines may also disrupt neuregulin-ErbB (NRG) re-
ceptor signalling to downstream cardiomyocyte pro-survival
cascades involving the serine-threonine protein kinase B /
AKT (whose origins stem from two human homologues of
the retroviral oncogene v-akt [26]), mitogen-activated protein
kinase (MAPK), phosphoinositide 3-kinase (PI3K) and extra-
cellular signal-related kinase (ERK1 / 2). NRG-1 controls cell
fate decisions in neuronal, skeletal myocyte, glial cells and
cardiomyocytes. The ErbB complexes themselves are impor-
tant modulators of cell growth. Overexpression of the NRG-1
receptor subunit ErbB2 is an important driver in certain neo-
plasms dependent on ErbB3 and ErbB2 (i.e. HER2+ breast
cancer). NRG-1 also binds ErbB4 and stimulates proliferation
of differentiated mononucleated cardiomyocytes, leading to
ErbB2/ErbB4 heterodimerization [27]. This leads to compen-
satory cellular hypertrophy, whereas deletion models demon-
strate dilated cardiomyopathy and systolic dysfunction in the
presence of pressure overload [28]. Anthracyclines appear to
increase ErbB2 expression after chronic doxorubicin expo-
sure, but decrease ErbB4 expression after acute doxorubicin
dosing, potentially explaining the time course of anthracycline
cardiomyocyte toxicity [18].
Other Targets
The Ras-related C3 botulinum toxin substrate 1 – guanosine
triphosphate enzyme (Rac1 GTPase) subunit also contributes
to anthracycline cardiotoxicity by fragmenting histone-
associated DNA and activating the programmed cell death
caspase-3 (cysteine-aspartic acid protease) enzyme via nico-
tinamide adenine dinucleotide phosphate (NADPH) oxidase
activation and ROS [29]. Other mechanisms include de-
creased c-Kit + cardiac progenitor cells following juvenile
anthracycline exposure, leading to impaired compensatory
mechanisms for stress and vascular injury repair, [30] and
myofibril instability due to titin proteolysis and increased cal-
cium sequestration, which may lead to diastolic dysfunction
[28]. Together, these two mechanisms may partly explain the
late cardiotoxicity seen in childhood cancer survivors manifest
as early dilated cardiomyopathy followed by a period of com-
pensated systolic function before a decompensated phenotype
of restrictive physiology, decreased myocardial wall thickness
and ejection fraction. [31].
Cardiotoxicity – in Search of A Consensus Definition
The cardiovascular side effects of anthracycline anti-tumour
agents became apparent soon after their widespread use in the
1970s, but the more recent concept of ‘cardiotoxicity’ has no
standard definition. The mechanisms, detection, prevention,
and protection from anthracycline cardiotoxicity remain rele-
vant today because of its long legacy of treated patients and
because cumulative dose-related toxicity constrains treatment.
We deconstruct ‘cardiotoxicity’ according to patient age, time
course, and affected cardiac domain (clinical decompensation,
structural change, biomarker rise, or arrhythmia).
Fig. 2 Doxorubicin staining
shows sequestration in (L)
cardiomyocytes and (R) malig-
nant cervical cancer cells (courte-
sy Dr. I Piotrowska)
Cardiovasc Drugs Ther (2017) 31:63–75 65
Incidence
The incidence of cardiotoxicity varies according to how it is
defined. Cardiotoxicity spans a continuum of frequency and
severity, ranging in seriousness from overt clinical symptoms
requiring urgent hospital admission, to an asymptomatic de-
tectable structural change on cardiac imaging or new onset
arrhythmia, to a measurable biomarker rise before symptom-
atic, structural or electrical change is detectable. These sub-
types of cardiotoxicity occur as clinical decompensation in 2–
4%, sub-clinical structural change in 9–11%, arrhythmia (e.g.
AF) in >12%, and biomarker rise in 30–35% of cancer che-
motherapy patients.
Cardiotoxicity, first observed in adult cancer patients as clin-
ical congestive heart failure (CHF), characterised by pulmonary
oedema, fluid overload, and effort intolerance, was initially re-
ported in 1979 by Von Hoff et al. at 2.2% overall with a cumu-
lative doxorubicin dose-dependent incidence of CHF of 3%, 7%,
and 18% at 400, 550, and 700 mg/m2, respectively [32]. A fur-
ther retrospective pooled analysis of three breast and lung cancer
trials by Swain et al. documented higher rates of CHF – 4.7%,
26%, and 48% at 400, 550 and 700 mg/m2, respectively - pro-
viding the current basis to limit lifetime cumulative doxorubicin-
equivalent exposure to ≤450 mg/m2 in patients without prior
chest radiotherapy [33]. Further studies of biopsy-confirmed
doxorubicin cardiomyopathy documented alarmingly poor prog-
nosis – hazard ratio for fatal cardiotoxicity 3.46 and 50% mor-
tality at two years – akin to restrictive and infiltrative cardiomy-
opathies [34].
Sub-clinical cardiotoxicity is commonly defined on cardiac
imaging as clinically asymptomatic left ventricular systolic
dysfunction (LVSD) with a fall in left ventricular (LV) ejec-
tion fraction (EF) by >10% points to a value of EF < 50% [35,
36]. When defined as radionuclide MUGA ejection fraction
(EF) fall of more than 10% to an absolute value <50%,
cardiotoxicity occurred with a cumulative incidences in 9%,
18%, 38%, and 65% of patients at 250, 350, 450 and 550 mg/
m2, respectively, and Schwartz et al. classified 14.8% (220 of
1487) doxorubicin-treated cancer patients as high risk on the
basis of abnormal falls in MUGA LVEF prior to the onset of
clinical congestive cardiac failure, thereby establishing LVEF
as predictive of clinical heart failure. A dose-escalation curve
and reduction in %EF by MUGA scan were reported in breast
cancer patients by Speyer et al., − 4% at 275–400mg/m2, 15%
at 400–500 mg/m2, 16% at 500–699 mg/m2, 18% at 800–
899 mg/m2, and 21% at 900–999 mg/m2.
Smith et al. [11] reported significantly increased odds ratio
for clinically symptomatic (OR 5.4 [95% CI 2.3–12.6]) and
sub-clinical fall in LVEF (OR 6.25 [CI 2.58–15.13]) for
anthracycline cardiotoxicity in their meta-analysis of 55
anthracycline cancer trials. Hequet et al. [35] documented a
27% incidence of 5-year sub-clinical cardiotoxicity in 39 of
141 adult lymphoma patients (mean doxorubicin dose
300 mg/m2, mean age 54 years), using echocardiographic
criteria of fractional shortening (FS) < 25% (equivalent to
EF < 50%). Predictors for sub-clinical cardiotoxicity were
increasing age, male sex, doxorubicin dose and being
overweight.
In the modern contemporary series by Cardinale et al.,
cardiotoxicity (defined as an echocardiographic LVEF de-
crease of more than 10% to EF < 50%) occurred in 9% of a
mixed group of 2625 adult patients (aged 50 ± 13 years, 51%
breast cancer, 28%Hodgkin lymphoma, 74%women) follow-
ed up for a median period of 5.2 years [37]. Of note, 98% of
cases of asymptomatic LVEF decline were detected prospec-
tively in the first 12 months of follow-up after chemotherapy,
implicating early cardiotoxicity rather than a Blate effects
phenomenon^ in adults as the dominant natural time course
of anthracycline chemotherapy.
Relying solely on LVEF as a sub-clinical imaging marker
of cardiotoxicity is problematic. The measurement itself is
calculated by various echocardiographic techniques, each
with its own limitations. Thavendiranathan et al. reported the
minimum detectable change in EF by the same observer was
9%, 10%, and 4.8% by 2D bi-plane, tri-plane, and 3D
methods; whereas the minimum detectable change in EF by
different observers on different acquisitions (interobserver
test-retest) was 13%, 16%, and 6% for 2D bi-plane, tri-plane
and 3D methods [36]. Thus, the reproducibility and precision
of echo-based LVEF measurement may be worse than the
Basymptomatic 10% fall in EF^ which is commonly used as
the decision threshold to define cardiotoxicity (Table 1).
These limitations have led to development of more reliable
measurements based on myocardial deformation that detect
early structural change before a fall in EF. A relative change
in 2D speckle-tracking echocardiographic global longitudinal
strain (GLS) of 10 to 15% (95% CI = 8.3% - 14.6%) or an
absolute GLS Bgreater^ than −19% predicted cardiotoxicity
defined as a fall in EF with sensitivity of 65–86% and speci-
ficity of 73–95%.
The Role of Cardiac Troponins
Cardiac troponin is central to the universal definition of acute
coronary syndrome (ACS), and its release is predictive of
Table 1 Equivalent anthracycline dosages relative to doxorubicin
(adapted from [38])
Anthracycline Relative
cardiotoxicity
Incidence of LVSD /
HF
Doxorubicin 1 3–5% at 400 mg/m2
Epirubicin 0.7 0.9–11.4% at 900 mg/m2
Idarubicin 0.53 5% at 150 mg/m2
Liposomal doxorubicin 0.5 2% at 900 mg/m2
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prognosis in myocardial infarction and other forms of heart
disease [39–46]. When measured as an early biomarker of
cancer cardiotoxicity, troponin rise occurs consistently in
21% - 40% of patients after anthracycline chemotherapy, irre-
spective of assay type [47–49]. Though troponin-I and
troponin-T levels are not directly comparable across the avail-
able assays, representative levels ranged from 11 to 120 ng/L
in low-dose, and 160 to more than 1900 ng/L in high-dose
anthracycline regimens (see Table 2) [56]. In the setting of
cancer chemotherapy cardiotoxicity, the rise in troponin may
quantify both cardiomyocyte apoptosis and myofibril degra-
dation more than necrosis and predicts cardiotoxicity defined
as fall in LVEF as well as major adverse cardiovascular events
(MACE).
Baseline troponin levels may be elevated due to the burden
of malignant disease itself. Auner et al. reported a baseline
troponin-T levels >70 ng/L in 3.8% of 78 mixed acute mye-
loid and non-Hodgkin lymphoma patients [57]. Lipshultz
et al. documented baseline increased troponin-T levels
>10 ng/L in 10% of 119 paediatric acute lymphoblastic leu-
kaemia, associated with a ten-fold increase in white-cell count
(300 × 103/mm3 vs. 27 × 103/mm3) and significant blast crisis
(89% vs. 57.5%) [53], reflecting the cardiotoxic effects of
profound leucocytosis in the circulation, and in particular,
the coronary circulation even before anthracycline exposure
[58–60]. Cardiac troponin-T levels in the unprotected control
cohort of the study were elevated in 50% of 76 patients, with
multiple troponin-T elevations occurring in 37%.
Cancer itself may be arrhythmogenic, and its treatments
may increase supraventricular tachyarrhythmias and atrial fi-
brillation [61, 62]. Baseline AF incidence in cancer was re-
ported as 2.4% and new onset AF occurred in a further 1.8%
in a large cohort of 24,125 cancer patients [63]. Early short
term arrhythmia studies documented increased ventricular
ectopy at 1 h post-infusion in 3%, rising to 24% during 1 to
24 hours of Holter monitoring.
Time Course of Cardiotoxicity
The time course of cardiotoxicity varies depending on patient
age at time of exposure and the class effect of chemotherapy
drugs, where childhood cancer survivors experience exponen-
tially rising risk for cardiovascular events (a Blate effect^), but
older adults’ cardiovascular risk manifests earlier and is de-
pendent on the number of conventional co-existing cardiac
risk factors— hypertension in particular.
Kero et al. [64] reported increased hazard ratios (HR) 3.6
and 13.5 times that of age-matched sibling controls for cardio-
myopathy in cancer survivors aged 0–19 years and 20–
34 years, respectively, as well as HR 3.3 and 1.8 for ischaemic
heart disease in the same age groups, respectively. Armstrong
et al. have defined a long period of latency in childhood and
young adult cancer survivors of 20 or more years in Ta
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longitudinal cohort studies. Further evidence of individual
cardiac risk and premature cardiac ‘ageing’ was documented
in breast cancer survivors (treatedwith a mix of anthracyclines
and radiotherapy). Peak oxygen consumption scores in breast
cancer survivors were equivalent to scores in controls 20 years
older – mean VO2 peak (mVO2) = 19.5 ml/kg/min in breast
cancer survivors aged 50 years compared to mVO2 = 19.3 ml/
kg/min in a cohort of healthy 70 year old controls [65]. Thus
evidence of early cardiac aging in individual cancer survivors
bears striking similarities to the epidemiological outcomes in
adult survivors of childhood cancers.
Childhood Cancer Cardiotoxicity
Long-term outcomes in children treated for acute lymphoblas-
tic leukaemia with or without dexrazoxane cardioprotection
document a time course of sub-clinical left ventricular disease
that is distinct to that of adults [66]. Cancer-treatment related
cardiotoxicity is increased inyounger (especiallyage<7years),
female patients, chest radiotherapy, higher doses of
anthracyclines, as well as higher body fat composition. The
reasons for this are not completely understood. Anthracycline-
mediated reduction in C-kit + cardiac progenitor cells
resulting in impaired myocardial growth (and reduced LV
mass) during increased somatic growth may amplify
cardiotoxic vulnerability from the loss of myocytes during
anthracycline exposure in childhood [67]. Autopsy studies in
human hearts have documented preferential accumulation of
doxorubicin in cardiac over skeletal and smooth muscle with
gradual conversion to doxorubicinol [68]. Paediatric cancer
treatments may be particularly cardiotoxic as neonatal murine
heart mitochondria appear ‘primed’ for apoptosis via the B-
cell lymphoma 2 / BCL-2 homology (BCL2-BH3) pathway
compared to apoptosis-refractory adult mitochondria [69].
These putative mechanisms, together with diastolic dysfunc-
tion from increased calcium sequestration and titin proteoly-
sis, may partially explain why paediatric cancer survivors
demonstrate a decompensated phenotype after anthracycline
exposure. Childhood cancer survivors demonstrate progres-
sive sub-clinical left ventricular disease, as somatic growth
outpaces paediatric cardiomyocyte growth, manifest as early
dilated cardiomyopathy followed by a period of compensated
systolic function and later restrictive physiology (normal to
low cavity size, reduced ventricular wall thickness and frac-
tional shortening), a distinctly different time course compared
to adult cancer survivors.
Controversies in Cardiotoxicity: Type 1 Vs. Type 2
and the Early Vs. Late Paradox
The concept of reversible (‘type 1’) and irreversible (‘type 2’)
cardiotoxicity was proposed with the introduction of HER2/
ErbB receptor blockers such as trastuzumab (Herceptin ®)
[70]. Here the argument was that anthracycline cardiotoxicity
was persistent, dose-related and irreversible (type 1), whereas
trastuzumab cardiotoxicity was reversible, not dose-related
and LV ‘function’ recoverable upon discontinuation of
trastuzumab. This concept has not been without controversy
because some cardioprotection studies suggest that
anthracycline cardiotoxicity maybe reversible if detected
within 3–6 months of a decline in ejection fraction [71, 72].
Furthermore, the typical regimen of trastuzumab was admin-
istered concomitantly with anthracyclines, though currently it
is administered sequentially after anthracyclines, thereby con-
founding any lone effect of trastuzumab with anthracycline
exposure.
Cardinale et al. prospectively followed 2625 cancer pa-
tients and documented a single linear time course for
anthracycline cardiotoxicity defined as a fall in LVEF [37].
In this cohort, followed up for a median of 5.2 years, 98%
of cardiotoxicity was documented in the first 12 months’ fol-
low-up, without a bimodal Bearly^ and subsequent Blate
effects^ distribution, contrary to conventional wisdom – cast-
ing dispersions on the widely held belief of ‘early’ and ‘late’
cardiotoxicity in adult cancer survivors. Cardinale argued
against the classic ‘late’ cardiotoxicity paradigm in adults,
because prior studies detecting late phenomena were retro-
spective, and instead proposed that ‘late’ cardiotoxicity was
‘early’ cardiotoxicity that had escaped detection at an earlier
stage.
Outcomes
The long term cardiovascular outcomes of cancer survivors
vary according to several risk profiles. The predictors for car-
diovascular outcomes after cancer survival include age at time
of diagnosis, female gender in childhood cancer survivors,
chest radiotherapy, time since cancer treatment [13] and
anthracycline dosage [73]. Kero et al. reported increased HR
for cardiomyopathy =4.6 (and strikingly high HR 13.5 for age
0–19 y) and ischaemic heart disease =1.8 compared to sibling
controls for young adult cancer survivors aged <35 years.
The importance of cardiology follow-up for late
cardiotoxicity due to chemotherapy is particularly important
in childhood cancer survivors. The cumulative incidence of
adverse cardiovascular outcomes by age 45 years in 10,724
childhood cancer survivors (acute lypmphoblastic leukaemia
[ALL] 30%, Hodgkin Lymphoma [HL] 12.8%,Wilms tumour
9.6%, sarcoma 8.7%) are strikingly higher [73]. The incidence
in childhood cancer survivors compared to sibling controls of
coronary artery disease, heart failure, and valvular disease was
5.3% vs. 0.9%, 4.8% vs 0.3%, and 1.5% vs. 0.1%, respective-
ly, signifying an increased relative risk (RR) between 6 and
16. Hypertension alone was associated with an increased RR
of 5.6 of cardiac death. This substantial body of long term
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follow-up has produced an individualized childhood cancer
survivor risk calculator [74].
Cardiotoxic morbidity and mortality occur at higher nu-
merical epirubicin doses than for doxorubicin. Dose-related
NYHA class II or worse congestive heart failure (CHF) inci-
dence occurred in 1.9% at 800 mg/m2, 4% at 900 mg/m2, and
15% at >1000 mg/m2 in a series of 469 epirubicin-
treated breast cancer patients [75]. CHF occurring at a
median onset of 57 days with overall 38% mortality and
median survival of 162 days and 125 days if patients
had received radiotherapy.
Cardiac mortality is an increasingly important determinant
of overall prognosis after cancer. Cardiovascular death was the
leading cause of death surpassing recurrent breast cancer
(15.9% vs. 15.1%) after median nine-year follow up in
63,566 female breast cancer patients [13]. Women were more
likely to die of cardiovascular causes than from breast
cancer as they aged, with cardiac death overtaking can-
cer death after nine years survivorship. In childhood
cancer survivors, cardiac deaths accounted for 13% of
deaths after 45 years’ survival, and the annualised car-
diac death rate exceeded that of cancer recurrence (0.14% vs.
0.05%) after 30 years’ survivorship [76]. Thus with ever lon-
ger cancer survivorship, cardiovascular mortality supervenes
cancer mortality.
Pregnancy Outcomes
Cancer is the second most common cause of death during the
female reproductive years and it occurs in 1 in 1000 pregnan-
cies with breast, cervical, lymphoma and leukaemia’s the most
common malignancies [77]. Lymphoma occurs in 1 in 6000
pregnancies, and identified risks include increasing maternal
age and HIV-related non-Hodgkin’s lymphoma in developed
and developing countries, respectively [78]. Termination of
pregnancy is recommended when malignancy is diagnosed
during the first trimester due to the likelihood of aneuploidy
and disrupted organogenesis, but until recently malignancy
management in later pregnancy was based on small case re-
port data. Pinnix et al. reported promising 5-year long term
outcomes in lymphoma (HL and NHL) diagnosed during
pregnancy. In a retrospective series of 39 pregnant women
(median age 28 years), there were three terminations. In the
remaining 36 pregnancies, 24 elected to have antenatal che-
motherapy and 12 elected to defer treatment until after deliv-
ery. There were 4 miscarriages (two in first trimester, all four
in the antenatal chemotherapy group), and the median gesta-
tional age of delivery was 37 weeks. There were no reported
foetal anomalies. Progression free survival at 5 years was
74.7%, (overall survival =82.4%). This compared favourably
with 5-year HL survival of 86% and NHL of 69.5% in women
who were not pregnant [4].
The Search for Cardioprotective Therapies
A number of potential cardioprotective techniques and thera-
pies have been explored ranging from modified anthracycline
preparations, anti-oxidants, free radical scavengers, renin-
angiotensin-system antagonists, cardioselective beta-blockers
to statins. Whilst many show promise in animal studies, the
clinical studies have had mixed results.
Modified analogues of doxorubicin such as epirubicin and
liposomal doxorubicin are relatively less cardiotoxic than con-
ventional doxorubicin. Epirubicin was associated with de-
creased odds ratio for clinical 0.39 (95%CI 0.20–0.78) and
sub-clinical fall in LVEF (OR 0.30 (95% CI 0.16–0.57) [11].
In a meta-analysis, epirubicin had lower rates of clinical
cardiotoxicity (OR 0.39, 0.2 to 0.78; p = 0.008; I2 = 0.5%)
and subclinical cardiotoxicity (OR 0.30, 0.16 to 0.57;
p < 0.001; I2 = 1.7%) than doxorubicin without compromising
anti-tumour efficacy [11]. Liposomal doxorubicin also had
lower rates of clinical cardiotoxicity (OR 0.18, 0.08 to 0.38;
p < 0.001; I2 = 0%) and subclinical cardiotoxicity (OR 0.31,
0.20 to 0.48; p < 0.01; I2 = 48.5%) than doxorubicin, again,
without compromising efficacy. Liposomal doxorubicin and
epirubicin have similar levels of cardiotoxicity (RR 1.15, 0.47
to 2.84; p = 0.754) [11]. Continuous infusion doxorubicin was
compared against bolus infusion in children with acute lym-
phoblastic leukaemia. There were similar levels of LV systolic
dysfunction, cavity dilatation, reduced wall thickness and LV
mass at 8 years, and thus no cardioprotection in children [79].
N-acetylcysteine has antioxidant properties and was there-
fore hypothesised to be of benefit due to the ROS hypothesis.
However, clinical studies have failed to demonstrate a benefit
fromN-acetylcysteine in preventing or reversing doxorubicin-
induced cardiomyopathy. In a study of doxorubicin-naïve pa-
tients with normal left ventricular function, patients given N-
acetylcysteine 1 h before their first dose of doxorubicin had
similar histological damage (tubular and mitochondrial area)
on endomycardial biopsies taken at 4 and 24 h after doxoru-
bicin administration to controls. In a small randomised con-
trolled trial of 19 disease-free sarcoma patients with
doxorubicin-induced cardiomyopathy, patients receiving N-
acetylcysteine 5.5 g/m2 daily for 30 days (n = 11) showed
no difference in left ventricular ejection fraction at rest or
during exercise compared to controls [80]. The largest
randomised controlled trial was performed by Myers et al.
who randomised 54 patients with breast cancer, nodular lym-
phoma or metastatic soft tissue sarcoma to receive either N-
acetylcysteine 5.5 g/m2 orally prior to doxorubicin or placebo.
The rates of clinical heart failure were similar between the
intervention and control groups (12.5% vs 10%, p = 0.77)
[81].
Calcium antagonists have been studied in two small clini-
cal trials. Milei et al. studied prenylamine in 26 adults with
solid tumours undergoing doxorubicin chemotherapy. One
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patient in the control group (n = 13) and no patients in the
intervention group (n = 13) developed cardiomyopathy [82].
Kraft et al. studied low-dose verapamil in adult patients with
acute myeloid leukaemia [83]. One patient in the control
group (n = 17) and no patients in the intervention group
(n = 13) developed heart failure (no significant difference).
Amifostine, a broad-spectrum cytoprotective agent,
showed promise in animal models, where it prevented
doxorubicin-induced cardiotoxicity [84, 85]. However, this
did not translate in a clinical study of 28 children with osteo-
sarcoma treated with cisplatin and doxorubicin, where no car-
diac benefit was observed. Moreover, amifostine was poorly
tolerated, with 93% of patients suffering grade 3/4 vomiting
compared to 7% in the control group.
Coenzyme Q10 was studied in a mixed cohort of 20 chil-
dren with acute lymphoblastic lymphoma (ALL) and HL.
Children in the control group had a reduction in interventric-
ular septum wall thickening, measured by echocardiography,
following anthracycline chemotherapy. The authors suggested
a protective effect from coenzyme Q10, though this has not
been replicated in larger studies [86]. Despite their promise for
providing cardioprotection, free radical scavengers have failed
to show protection in clinical studies. Probucol, a lipid-
lowering agent and antioxidant, has shown to be protective
against doxorubicin-induced cardiomyopathy without
compromising antitumour efficacy in rats and mice.
Animal studies using dexrazoxane had mixed results
in vivo. Deferiprone (Ferriprox) demonstrated anthracycline
cardioprotection in a rat model [87, 88]. However,
dexrazoxane is the only iron chelator that has been licenced
for clinical use in (breast) cancer patients undergoing extended
anthracycline dosing in excess of 300 mg/m2.
Dexrazoxane’s cardioprotective mechanism against
anthracyclines was considered to be due to iron chelation,
preventing anthracycline-iron binding and the subsequent
ROS formation. However, cardioprotection seems to be ex-
clusive to dexrazoxane and deferriprone rather than a class
effect as other iron chelators, such as deferasirox, have not
shown cardioprotection [89]. Dexrazoxane binds to topoisom-
erase-2, with cardioprotection conferred via top-2β, but the
role of top-2α also formed the controversial hypothesis for
potentially reduced anti-tumour efficacy and its role in malig-
nant proliferation.
Dexrazoxane has largely been evaluated in women with
advanced breast cancer and adults with sarcoma, and its cur-
rent approval is for extended anthracycline dosing. A meta-
analysis showed that dexrazoxane administration alongside
doxorubicin or epirubicin reduced the rates of clinical
cardiotoxicity (OR 0.21, 0.13 to 0.33; p < 0.000 l; I2 = 0%)
and subclinical cardiotoxicity (RR 0.33, 0.20 to 0.55;
p < 0.0001 l I2 = 0%) compared to doxorubicin or epirubicin
alone [11]. Asselin et al. reported the cardioprotective effects
of dexrazoxane vs doxorubicin-only in 537 children and
adolescents with T-cell acute lymphoblastic leukaemia (T-
ALL) or advanced lymphoblastic Non-Hodgkin lymphoma
(NHL) [90]. At three years, LV function assessed by fraction
shortening was significantly lower in the doxorubicin-only
group than the dexrazoxane group (p = 0.05). Five-year event
free survival and rate of secondary malignancies was not sta-
tistically different between the dexrazoxane group and
doxorubicin-only group (76.7 ± 2.7% vs 76.0 ± 2.7%,
p = 0.9, and 0.8 ± 0.5% vs 0.7 ± 0.5%, p = 0.17, respectively).
Further meta-analysis of five randomised control trials sug-
gested dexrazoxane was associated with a borderline increase
in secondary malignant neoplasms that was not statistically
significant (absolute incidence 2.7% [17/635] vs. 1.1%
[7/610], p = 0.06).
In addition to their lipid-lowering effects, statins also have
anti-inflammatory and anti-oxidant effects [91]. They have
been postulated to increase anti-tumour efficacy but clinical
studies in malignant melanoma and colorectal cancer have not
observed this. In a small trial of patients undergoing
anthracycline-containing chemotherapy regimes, patient were
randomised to receive atorvastatin 40 mg (n = 20), com-
menced before their chemotherapy and continued for
6 months, or control (n = 20). The primary endpoint was
reduction in LVEF to <50%. One patient (5%) in the statin
arm and five patients (25%) in the control arm developed
LVEF <50%, however, this did not reach statistical signifi-
cance (p = 0.18). The mean change in LVEF, left ventricular
end-diastolic diameter and end-systolic diameter (LVEDD
and LVSD) from baseline to 6 months for the statin group
and control group were 1.3 ± 3.8 vs −7.9 ± 8.0%, p < 0.001;
−0.15 ± 4.0 vs 2.0 ± 3.3 mm, p = 0.021; and −1.35 ± 4.0 vs
2.1 ± 1.8 mm, p < 0.001, respectively [92]. In a retrospective,
observational cohort study of 201 women receiving
anthracyclines for newly diagnosed breast cancer, uninterrupt-
ed statin therapy had a reduced risk of heart failure compared
to propensity-matched controls (hazard ratio 0.3, 95% CI:
0.1–0.9, p = 0.03). However, this finding may have been con-
founded by a greater ACE inhibitor and β-blocker use in the
statin group compared to controls (38.8% vs 17.2%, p < 0.001
and 38.8% vs 14.9%, p < 0.001, respectively) [93].
Carvedilol is a non-selective β-antagonist with some α-
antagonist effect. It also inhibits NADH dehydrogenase,
found in complex I of the mitochondria, and has antioxidant
activity. It has therefore received considerable interest in
cardioprotection against anthracycline-induced cardiotoxicity
and been studied in isolation and in combination with ACE
inhibitors.
The OVERCOME trial (preventiOn of the left Ventricular
dysfunction with Enalapril and caRvedilol in patients submit-
ted to intensive chemOtherapy for the treatment of Malignant
hEmopathies) is the largest randomised controlled trial of
combined ACE inhibitors and carvedilol [94]. Ninety adult
patients with normal left ventricular ejection fraction (LVEF)
70 Cardiovasc Drugs Ther (2017) 31:63–75
and newly diagnosed haematological malignancy were
randomised to either enalapril + carvedilol or control. The
primary endpoints were changes in LVEF assessed by trans-
thoracic echocardiography and cardiac magnetic resonance
(CMR) at six months from baseline. The population com-
prised of 36 patients with acute leukaemia (acute myeloid
leukaemia 30 and acute lymphoblastic leukaemia 6) and 54
were undergoing autologous stem cell transplant for
Hodgkin disease (n = 9), non-Hodgkin lymphoma
(n = 23), and multiple myeloma (n = 22). Doses of
enalapril and carvedilol were similar to heart failure
studies (8.2 ± 5.9 mg and 26.1 ± 18.2 mg, respective-
ly). Left ventricular ejection fraction declined at six
month in the control group on both echocardiography
and CMR (−3.28% (95%CI: -5.49 to −1.07) and
−3.04% (95%CI: -6.01 to −0.070, respectively), but
was preserved in the intervention group (−0.17 (−2.24
to 1.90) on echocardiography and 0.36 (−2.41 to 3.13)
on CMR). Interestingly, the pre-specified subgroup anal-
ysis showed that patients with acute leukaemia had a
greater degree of LVEF decline, with mean − 6.4%
(95%CI: -11.88 to −0.87) compared to −1.01%
(95%CI: -4.46 to 2.45) in patients undergoing autolo-
gous stem cell transplant.
Prompt initiation of ACE inhibitors and β-blockers when
LVEF declines is important for recovery of function [71, 95].
Cardinale et al. randomised patients with raised troponin I
after high-dose anthracycline-containing chemotherapy to ei-
ther enalapril (n = 56) or control (n = 58). Treatment was
started one month after the completion of chemotherapy and
continued for a year. The primary endpoint was a reduction in
LVEF >10% to LVEF <50%. The maximum tolerated dose of
enalapril was 16 ± 6 mg daily. Twenty five control subjects
(43%) and no intervention subject had a reduction in LVEF to
<50% (p < 0.001) [72]. Furthermore, their work documented
that prompt initiation of treatment was an important determi-
nant of LV functional recovery.
In their larger prospective cohort study of 2625 patients
undergoin anthracycline chemotherapy, Cardinale et al. mea-
sured LVEF by serial echocardiography for a median follow-
up of 5.2 years (quartile 1 to quartile 3, 2.6–8.0 years) [37].
Cardiotoxicity, defined as a reduction in LVEF of ≥10% to
<50%, was seen in 226 (9%). The vast majority (98%) oc-
curred within the first 12 months, with median time to devel-
opment of 3.5 months (quartile 1 to quartile 3, 3–6 months)
after completing chemotherapy. Prompt initiation of enalapril
and carvedilol (n = 186) or enalapril alone (for those recruited
before 1999, n = 40) at the time of detection of cardiotoxicity
resulted in full recovery of LVEF, defined as return to baseline,
in 25 (11%) and partial recovery, defined as an increase in
LVEF ≥ 5%, in 160 (71%) patients [95]. This study also raised
the intriguing observation that 98% of LV functional decline was
detected in the first 12 months – challenging the paradigm of
early vs. late cardiotoxicity observed in legacy retrospective
studies.
Studies of carvedilol monotherapy are smaller. In adult
females with non-metastatic breast cancer randomised to car-
vedilol (n = 30) or placebo (n = 40), commencing one week
before starting doxorubicin and finishing one week after the
final cycle, those taking carvedilol showed no change in their
LV strain measurements from baseline to after chemotherapy,
whereas patients taking placebo showed significant deteriora-
tion. Neither group showed significant deterioration in their
LVEF [96]. Another small study randomised patients to car-
vedilol (n = 25) or placebo (n = 25) and demonstrated that the
carvedilol group maintained LVEF, whereas the control group
had a reduction in LVEF at 6 months compared to baseline
(70.5 vs 69.37, p = 0.3, and 68.9 vs 52.3, p < 0.001,
respectively).
Carvedilol has also shown a benefit in children aged 6–
12 years with acute lymphoblastic leukaemia treated with
doxorubicin [97]. Patients were randomised to carvedilol for
five days before doxorubicin (n = 25) or doxorubicin alone
(n = 25). Patients in the intervention arm had a higher frac-
tional shortening (FS) one week after the last dose of doxoru-
bicin compared to pre-chemotherapy (baseline 34.0 ± 4.5 vs
39.5 ± 6.3, p ≤ 0.05), whereas patients without carvedilol had
a reduction in FS (40.0 ± 4.6 vs 33.5 ± 6.2, p ≤ 0.05). Diastolic
parameters (E, A and E/A) were not different between the two
groups. Similar findings were seen by Ewer between pre-
doxorubicin and one-week after completion of chemotherapy
in paediatric patients, aged 7 months to 15.5 years [98].
Nebivolol, a selective β1-antagonist with nitric oxide vasodi-
lator properties, demonstratred increased contractility in ani-
mal studies, and cardioprotrection via preserved LVEF com-
pared to placebo in patients with breast cancer receiving
doxorubicin [99].
The recent PRADA trial (Prevention of cardiac dysfunction
during adjuvant breast cancer therapy) compared the
cardioproctive properties of candesartan and metoprolol in
120 patients with early breast cancer undergoing adjuvant
FEC chemotherapy (fluorouracil, epirubin and cyclophospha-
mide) in a 2 × 2 factorial, randomised, placebo-controlled,
double-blind study [100]. Patients were randomised to receive
candesartan-metoprolol, candesartan-placebo, metoprolol-
placebo or placebo-placebo. The primary endpoint was a
change in cardiac magnetic resonance (CMR)-LVEF from
baseline to the end of chemotherapy. Patients receving
candesartan had no change in their LVEF (0.8, 95% CI: -0.04
to 1.9) after chemotherapy, whereas the non-candesartan group
had LVEF decline of 2.6% (95% CI: 1.5 to 3.8, p = 0.026). No
difference was seen between patients receiving metoprolol and
metoprolol-naïve patients, 1.6% (95% CI: 0.4 to 2.8) and 1.8%
(95% CI: 0.7 to 3.0), respectively. The PRADA results support
cardioprotective properties on a statistically measurable scale, if
not wholly clinically significant.
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Remote ischaemic conditioning (RIC) is another potential-
ly cardioprotective treatment that is currently under investiga-
tion in cancer patients [56]. This non-invasive non-pharmaco-
logical treatment is delivered via a blood pressure cuff as short
bursts of ischaemia and reperfusion in a peripheral limb. RIC
has been shown to protect the heart and other organs from
subsequent severe ischaemic injury [101–107], and demon-
strated lung protection in cancer surgery [103]. While the
mechanism of RIC is not fully understood, it appears to in-
volve a humoral and neural pathway that confers
cardioprotection by activating innate pro-survival pathways
that ultimately modulate common mechanisms in ischaemia
reperfusion injury and anthracycline cardiotoxicity such as
calcium overload, lipid peroxidation, ROS generation and mi-
tochondrial function [108].
Conclusion
The cardiotoxic mechanisms of anthracyclines may involve
the dual pathways of reactive oxidation species and
topoisomerase 2-beta and a final common pathway of
calcium overload, lipid peroxidation and mitochondrial
dysfunction. There is no universally accepted definition
of anthracycline cardiotoxicity, and thus its incidence
varies according to how it is defined. Clinically symp-
tomatic heart failure occurs in 2–4%, asymptomatic fall
in LVEF in 9–11%, arrhythmia in 12% or more, and
cardiac biomarker rise in 30–35% of treated patients.
Predictors of cardiotoxicity include cumulative dose,
cardiovascular risk factors and age of treatment.
It is essential that we continue to investigate ways of
protecting the heart following cancer chemotherapy, At pres-
ent the limited cardioprotective strategies available –
dexrazoxane, ACE-inhibitors, ARB, and beta-blockers – are
not in routine prophylactic use. New strategies are required to
help combat the cardiotoxicity derived from anthracycline and
other chemotherapies with novel agents such as NRG-1 that
target ErbB receptor or non-pharmacological and non-
invasive techniques, such as remote conditioning, which acti-
vate endogenous pro-survival pathways in the heart.
In the forthcoming era of personalised cancer medicine and
targeted therapies, it may be tempting to consign the cardiac
effects of anthracyclines to history. However the large popu-
lation-at-risk, long latency in childhood cancer survivors, and
prospectively increased cardiac risk in adult cancer sur-
vivors have implications for cancer survivorship as a
cardio-oncology partnership. Thus, the increasing cancer
survivor population represents a strong motivator to ex-
plore larger randomised controlled trials in cancer
cardioprotection to prevent today’s cancer patient from
becoming tomorrow’s cardiac patient.
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